Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caplacizumab plus immunosuppressive therapy without first-line plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpura
jRCT2031230030Completed
- Sponsor
- Sanofi
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of caplacizumab, corticosteroids and rituximab in thrombotic thrombocytopenic purpura (TTP), sponsored by Sanofi. Primary endpoint: Proportion of participants achieving remission without requiring therapeutic plasma exchange. Started Jul 2023; status: completed.
02
Drugs
caplacizumabcorticosteroidsrituximab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on jRCT2031230030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230030.